Drugs / SUFLAVE
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SUFLAVE | — | 2023-06-15 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07215000 | Oct 2025 → Jan 2027 expected | colorectal cancer | Morehouse School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUFLAVE | “SUFLAVE is a combination, osmotic prescription laxative that may be used to cleanse the bowel in preparation for colonoscopy in adults.” NCT07215000 ↗ |
| Known as | Sulfave | “Drug: Sulfave” NCT07215000 ↗ |
| Route | Oral | “Drink 8 ounces of the solution every 15 minutes” NCT07215000 ↗ |